Page 67 - M. Immunology

Dracocephalum moldavica L. seed oil ameliorates DNCB-induced atopic
dermatitis-like symptoms in mice model

Jaeyoung Choi 1 , Eunsu Song 1 , Kyo-Yeon Lee 2 , Sung-Gil Choi 2 , Su Kang Kim 3 , Hui Jin 4 , Yun Hee Chang 1 , Jinah Hwang 1
1 Food and Nutrition, Myongji University, Yongin, Republic of Korea, 2 Food Science and Technology, Gyeongsang National University, Jinju, Republic of Korea, 3 Department of Biomedical
Laboratory Science, Catholic Kwandong University, Gangneung, Republic of Korea, 4 Center of Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, Republic of Korea
BACKGROUND AIM

Dracocephalum moldavica L. (DM) has unique nutritional characteristics in terms of This study was conducted to
lipid profile and various polyphenols. Due to its features, DM has been used for determine anti-atopic effect
dermal problem in North America and Eastern Europe. According to previous study, of DMS by supercritical fluid
there were various phytochemicals which may improve atopic dermatitis. However, extraction in vivo.
there is no report regarding anti-atopic effect of DM seed oil (DMS) in animal model.

METHODS

Figure 1. Experimental scheme of DM seed oil by supercritical CO 2 extraction
RESULTS

After 4 weeks treatment with DMS (2.5-10% v/v) in DNCB-
induced atopic mice model, increase in epidermal layer and
hyperkeratosis was observed in atopy-induced group (DNCB
only). However, DMS treatment showed decrease in epidermal
layer in a dose-dependent manner compared to vehicle control
group. In addition, significantly decrease in skin TEWL was
2
observed with 2.5-10% DMS (48.96-59.42 g/m /h) compared
with vehicle control (115.52 g/m /h). In terms of SCORAD index,
2
10% DMS-treated group decreased the indexes by 78% in
edema and by 60% in pruritus and dry skin compared to vehicle
group.
(A) (B)

Figure 2. Water content of stratum corneum (TEWL) and the severity of clinical Figure 3. Treatment of DMS efficiently attenuates severe
symptoms of the skin lesions (SCORAD Index) were reduced after DMS symptoms of experimental atopic dermatitis in DNCB-
treatment for 4 weeks. SCORAD Index was expressed for the following four induced BALB/c mice model after 4 weeks. (A) Cross
symptoms: erythema/ edema/ pruritus/ lichenification. (A) Transepidermal images of dorsal area lesions on the mice. (B) H&E–
water loss (TEWL) index. (B) SCORAD Index. stained images of dorsal skin.

CONCLUSION REFERENCES ACKNOWLEDGEMENTS

• Lee et al., Disease-specific primed This work was supported under the
DMS treatment showed human adult stem cells effectively framework of international
improvement of atopic dermatitis- ameliorate experimental atopic cooperation program managed by
like symptoms through indexes of the National Research Foundation
TEWL, SCORAD, optical images dermatitis in mice, Theranostics 2019, of Korea (2017R1A2B4010140).
and H&E staining in DNCB- 9(12):3608-3621
induced mice models. Therefore, • Motoyama et al., Anti-allergic
It is expected that DMS can be CONTACT INFORMATION
used as a functional cosmetic and effects of novel sulfated polysaccharide
pharmaceutical ingredient through sacran on mouse model of 2,4-Dinitro-1-
further research related to the fluorobenzene-induced atopic dermatitis, Jaeyoung Choi: n_jyoung92@naver.com
improvement of atopic dermatitis International Journal of Biological Jinah Hwang*: jhwang@mju.ac.kr
symptoms. Macromolecules 2018, 108, 112-118
*corresponding author